Product
Optimized NRTI backbone
1 clinical trial
1 indication
Indication
HIVClinical trial
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI BackboneStatus: Withdrawn, Estimated PCD: 2014-08-31